NCT05388695View on ClinicalTrials.gov

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

March 30, 2027

Study Completion Date

May 30, 2027

Conditions

19 and 22+ B Cell Hematologic Tumors19 and 20+ B Cell Hematologic Tumors

Interventions

BIOLOGICAL

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells

Single or sequential injection of CD19, CD20 and CD22 CAR T cells.

Trial Locations (1)

Unknown

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors

collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

NCT05388695 - To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors | Biotech Hunter | Biotech Hunter